Tongmaijiangzhi formula and its hypolipidemic compounds attenuate hyperlipidemia and hepatic steatosis via AMPK/NF-κB pathway.
第一作者:
Qian-Nan,Xu
第一单位:
Fujian Provincial Key Laboratory of Innovative Drug Target, School of Pharmaceutical Sciences, Xiamen University, Xiamen, 361102, China.
作者:
医学主题词
动物(Animals);高脂血症(Hyperlipidemias);降血脂药物(Hypolipidemic Agents);人类(Humans);NF-κB(NF-kappa B);AMP活化蛋白激酶类(AMP-Activated Protein Kinases);中草药(Drugs, Chinese Herbal);Hep G2细胞(Hep G2 Cells);男(雄)性(Male);金仓鼠(Mesocricetus);脂肪肝(Fatty Liver);信号传导(Signal Transduction);仓鼠亚科(Cricetinae);肝(Liver)
DOI
10.1016/j.jep.2025.120897
PMID
41274521
发布时间
2025-12-10
- 浏览2
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



